A new report says the Trump administration’s disruptions to a global AIDS relief program have forced organizations to close ...
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results